Health In Tech, Inc. reported the three months ended March 31, 2026 results: revenue $8.8 million, net income $1.6 million, or $(0.03) per diluted share, EPS $(0.03) per diluted share. Guidance reaffirmed.
“Health In Tech, Inc. (Nasdaq: HIT) (“Health In Tech” or “Company”), an AI-enabled InsurTech platform company, today announced its unaudited financial results for the three months ended March 31, 2026. First Quarter 2026 Overview ● Revenue increased 9.4% to $8.8 million from $8.0 million in the first quarter of 2025. ● Platform placed plan value 1 totaled $82.0 million. ● Adjusted EBITDA 2 totaled $(1.3) million, compared to $1.2 million in the first quarter of 2025, and reflected higher sales and marketing expenses for initiatives designed to drive long-term revenue growth. ● Net loss equaled $1.6 million, or $(0.03) per diluted share, compared to net income of $0.5 million, or $0.01 per diluted share, in the first quarter of 2025.”
Dustin Plantholt departed as Chief AI & Marketing Officer at Health In Tech, Inc..
“Following receipt of formal notice on April 27, 2026, Dustin Plantholt departed from his role as Chief AI & Marketing Officer of Health In Tech, Inc. (the “Company”), effective as of April 30, 2026, as part of a business transition and not as a result of any disagreement with the Company on any matter relating to its operations, policies or practices.”
Equity Issuances
Health In Tech, Inc. issued 5,600,000 shares of common stock to institutional investors for $1.25 per share.
“Health In Tech will issue an aggregate of 5,600,000 shares of common stock at a price of $1.25 per share”
Material Agreements
Health In Tech, Inc. entered into Placement Agency Agreement with Craig-Hallum Capital Group LLC (effective 2026-03-25).
“The Company also entered into a placement agency agreement (the “Placement Agency Agreement”) with Craig-Hallum Capital Group LLC, as the sole placement agent (the “Placement Agent”), dated March 25, 2026, pursuant to which the Placement Agent agreed to serve as the placement agent in connection with the PIPE in consideration for a cash placement fee and the reimbursement of certain out of pocket expenses, including those of its legal counsel.”
Material Agreements
Health In Tech, Inc. entered into Registration Rights Agreement with each Purchaser (effective 2026-03-25).
“In connection with the Purchase Agreement, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with each Purchaser.”
Material Agreements
Health In Tech, Inc. entered into Purchase Agreement with certain accredited investors valued at approximately $7.0 million (effective 2026-03-25).
“On March 25, 2026, Health In Tech, Inc., a Nevada corporation (the “Company”), announced that it has entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors (each, a “Purchaser” and collectively, the “Purchasers”) relating to a private investment in public equity financing (the “PIPE”) for an aggregate of 5,600,000 shares of its common stock, par value $0.001 per share (the “Shares”).”
Earnings Releases
Health In Tech, Inc. reported the fourth quarter and full year ended December 31, 2025 results: revenue Full year 2025 revenues were $33.3 million, net income Full year 2025 net income was $1.3 million. Guidance initiated.
“Health In Tech Announces Fourth Quarter and Full Year 2025 Financial Results ● Full year 2025 Revenues of $33.3 million, up 71% YoY ● Full year 2025 Adjusted EBITDA of $4.1 million, up 81% YoY”
Listing & Compliance Notices
Health In Tech, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“April 28, 2025, Health In Tech, Inc. (the “Company”) received a letter (the “Nasdaq Staff Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty (30) consecutive business days, the closing bid price for the Company’s Class A common stock was below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until October 27, 2025, to regain compliance. The letter stat”
Lynn Liang departed as Director at Health In Tech, Inc..
“On April 12, 2025, Lynn Liang notified the Board of Directors (the “Board”) of Health In Tech, Inc., a Nevada corporation (the “Company”) that she is resigning from the Board effective April 18, 2025.”
Sanjay Shrestha was elected as Director at Health In Tech, Inc..
“elected Sanjay Shrestha to serve as a member of the Board with immediate effect, for a one-year term”
Governance Changes
Health In Tech, Inc.: Amended and restated bylaws to increase the number of authorized directors from seven to 11 and change director term structure (effective 2025-02-25).
“On February 25, 2025, the Board of Directors (the “Board”) of Health In Tech, Inc., a Nevada corporation (the “Company”) adopted the Third Amended and Restated Bylaws of the Company (as amended and restated, the “A&R Bylaws”). The A&R Bylaws are effective as of February 25, 2025. The A&R Bylaws modify the Company’s existing Bylaws to increase the number of authorized directorships comprising the Board from seven directors to 11 directors.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.